Nanjing Vazyme Biotech Co Ltd Cash Flow Conversion Efficiency
Nanjing Vazyme Biotech Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.30 Million ≈ $11.02 Million USD) by net assets (CN¥3.84 Billion ≈ $562.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nanjing Vazyme Biotech Co Ltd (2017–2025)
Cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. This chart illustrates how Nanjing Vazyme Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Nanjing Vazyme Biotech Co Ltd stock price for real-time trading data and today's change.
Nanjing Vazyme Biotech Co Ltd Cash Flow Conversion Ratio Explained
Nanjing Vazyme Biotech Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nanjing Vazyme Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their cash flow conversion efficiency. Also see market cap of Nanjing Vazyme Biotech Co Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CoCreation Grass Co Ltd
SHG:605099
|
0.002x |
|
PC Connection Inc
NASDAQ:CNXN
|
0.015x |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
0.009x |
|
Tangshan Sanyou Chemical Industries Co Ltd
SHG:600409
|
0.029x |
|
Chang Wah Technology Co Ltd
TWO:6548
|
0.009x |
|
A.F.P. Provida
SN:PROVIDA
|
0.022x |
|
Kemper Corporation
NYSE:KMPR
|
-0.012x |
|
RAPT Therapeutics Inc
NASDAQ:RAPT
|
-0.082x |
Annual Cash Flow Conversion Efficiency for Nanjing Vazyme Biotech Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. Review 688105 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.79 Billion ≈ $554.78 Million |
CN¥233.16 Million ≈ $34.12 Million |
0.061x | +2605.02% |
| 2024-12-31 | CN¥3.94 Billion ≈ $577.07 Million |
CN¥-9.68 Million ≈ $-1.42 Million |
-0.002x | -104.99% |
| 2023-12-31 | CN¥4.03 Billion ≈ $589.61 Million |
CN¥198.40 Million ≈ $29.03 Million |
0.049x | -69.11% |
| 2022-12-31 | CN¥4.61 Billion ≈ $674.90 Million |
CN¥735.17 Million ≈ $107.58 Million |
0.159x | +6.66% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.95 Million |
CN¥616.80 Million ≈ $90.26 Million |
0.149x | -75.22% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
CN¥803.55 Million ≈ $117.59 Million |
0.603x | +693.51% |
| 2019-12-31 | CN¥200.02 Million ≈ $29.27 Million |
CN¥15.20 Million ≈ $2.22 Million |
0.076x | +415.63% |
| 2018-12-31 | CN¥166.08 Million ≈ $24.30 Million |
CN¥-4.00 Million ≈ $-585.21K |
-0.024x | +5.92% |
| 2017-12-31 | CN¥150.82 Million ≈ $22.07 Million |
CN¥-3.86 Million ≈ $-564.87K |
-0.026x | -- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more